Qualigenix bills infusion and ambulatory infusion center claims so the drug line, the administration codes and the authorization agree before a claim goes out. When the drug is a biologic or IVIG, one unit error on the J-code line can cost more than every administration code on the claim combined. Our CPC- and CCS-certified coders bill units to the vial, report wastage with JW or JZ, and match each dose to an active authorization.
Infusion center billing codes two things on every visit: the drug, by HCPCS code (usually a J-code) in the units its descriptor defines, and the administration, by CPT codes 96360–96379 for hydration, infusions and injections or 96401–96417 for chemotherapy and other highly complex drugs. Medicare Part B also requires a JW or JZ modifier on separately payable drugs from single-dose containers, and many biologics need prior authorization before the first dose. Qualigenix handles the coding, the authorizations and the follow-up, with a 98.2% first-pass clean claim rate on first submission. Call 786-259-0231 to talk through your center's claims.
Each visit needs a drug code with units that match the dose given, the NDC the payer expects, and administration codes that match the start and stop times in the chart. Without a documented stop time, an extra hour of infusion can't be billed with an add-on code such as 96366.
Biologics, IVIG, iron, chemotherapy agents and specialty injectables often need prior authorization, and an approval covers a specific drug, dose and date range. A dose change or a lapsed reauthorization can deny a claim for an infusion that was clinically appropriate.
Only one initial administration code is reported per encounter unless a separate IV site is medically necessary, and every other service goes on an add-on code. For facility reporting, CPT ranks infusions above pushes and pushes above other injections, puts chemotherapy and complex drug services above therapeutic ones of the same type, and ranks hydration last. In physician-office billing, the initial code follows the main reason for the visit.
Commercial plans with site-of-care programs tie an infusion approval to a setting, such as a hospital outpatient department, an ambulatory infusion center or the patient's home. If the authorization names a different site from the one that gave the infusion, the plan can deny the claim or pay a different rate.
Some infused and injected drugs are covered under a plan's pharmacy benefit rather than its medical benefit. If a center buys and bills a drug the plan covers only through specialty pharmacy, the medical claim denies and the center is left holding the cost of the drug.
Since July 1, 2023, Medicare Part B has required the JZ modifier when nothing is discarded from a single-dose container, and JW on a separate line for the amount that is. Medicare also requires the discarded amount to be recorded in the patient's chart.
Common infusion denials come from an authorization that doesn't match the drug or dates, units that don't match the documented dose, a missing or invalid NDC, an administration code billed out of hierarchy order, or a diagnosis outside the payer's drug policy.
NCCI edits bundle IV access (36000, 36410) into the administration codes, and hydration given at the same time as another drug infusion isn't separately reportable. Medicare coverage articles and commercial drug policies add their own diagnosis, dose and frequency limits.
Qualigenix reviews the drug line, the administration codes and the authorization together on each infusion claim it prepares, so a fix in one place doesn't create a mismatch in another.
Our coders convert the documented dose into the billing units of the drug's HCPCS descriptor, report the NDC with its unit of measure, and code administration time from the infusion record. Qualigenix holds 98.9% coding accuracy.
We request and track each authorization by drug, dose, units and date range, and flag reauthorizations before the approved window closes.
We choose the initial service by the rule that fits your setting, facility hierarchy or the reason for the visit, and report sequential, concurrent and additional-hour services with the matching add-on codes.
When a plan runs a site-of-care program, we confirm the approval names your center before the first infusion is given.
Before the first dose, we confirm whether the drug falls under the medical or pharmacy benefit, the patient's deductible and coinsurance, and any dose or visit limits.
We check that each single-dose drug line carries JW or JZ, that a JW line has a matching discarded amount in the chart, and that billed units don't exceed the vial sizes used.
We work infusion denials by root cause and appeal with the authorization, the infusion record and the payer's drug policy attached. Qualigenix overturns 79% of the denials it works, across 50,000 denials worked each month.
We audit infusion coding against NCCI edits, Medicare's drug administration and wastage rules, and payer drug policies, and report what we find to your team.
A 3-provider podiatry group with roughly 60% Medicare payer mix carried $412,000 in A/R, 38% of it past 120 days. Routine foot care claims (11720, 11721, 11055–11057) had stalled on inconsistent Q7/Q8/Q9 modifiers and class-finding documentation, so payers held or partially paid and nobody worked the remainder. Medicare crossover to secondaries was not being posted, and small patient balances were written off.
We ran a full A/R aging segmentation, worked claims by payer and denial reason rather than by date, rebilled the stalled routine-care claims with corrected modifiers, and reactivated secondary and crossover billing.
A solo podiatrist coding 320 encounters a month was stuck at 82% first-pass acceptance. Routine foot care went out without the systemic-condition diagnosis pairing and class findings Medicare requires, so it read as non-covered. Wound debridement was coded to the wrong depth (11042 for skin and subcutaneous where the note supported 11043 for muscle and fascia). Same-day E/M with a procedure went out without modifier 25 and got bundled.
We rebuilt the coding workflow: diagnosis-to-CPT pairing rules for at-risk foot care, correct Q-modifier logic, depth-based debridement coding tied to the operative note, and disciplined use of modifiers 25 and 59/XS.
A 2-location podiatry practice sat at a 19% denial rate, mostly Medicare routine-foot-care and nail-debridement rejections. The denials clustered in three buckets: medical-necessity rejections on routine foot care (missing qualifying diagnosis and class findings), frequency-edit denials on nail debridement billed inside the 60-day window, and missing Q modifiers that flagged services as non-covered.
We built a front-end denial-prevention layer, checking eligibility and coverage against payer LCDs before claims went out, plus a structured appeal workflow with documentation templates mapped to each denial reason.
Qualigenix codes each infusion service line to its own CPT or HCPCS family and the rules that apply to it.
96360 covers the first 31 to 60 minutes of IV hydration and 96361 each additional hour. Fluid used only to deliver a drug isn't billed as hydration, and hydration running at the same time as another infusion isn't separately reportable.
Qualigenix keeps infusion billing compliant by coding the drug and its administration only to what the infusion record shows: the dose given, the amount discarded, and the start and stop times. We apply NCCI drug administration edits and Medicare's JW/JZ policy as written, and we review each claim for overcoding and undercoding. Billing too few units leaves payment unclaimed, and billing too many invites recoupment. Our coding holds a 98.6% compliance and audit pass rate, with an over- and undercoding rate under 2%. All patient data is handled in HIPAA-compliant workflows under strict security controls.

Our infusion coders work from the chart, the vial log and the payer's drug policy, and they track CMS drug billing rules as they change. Medicare's latest error review of Part B drug claims shows where that work matters.
Qualigenix charges a percentage of collections, so the fee moves with what your center is paid. The rate depends on claim volume, drug mix and scope. Call 786-259-0231 to discuss your center.
Yes. We submit and track prior authorizations for biologics, IVIG, iron and specialty injectables by drug, dose and date range, and flag reauthorizations before an approval lapses.
Only one initial administration code is billed per encounter, and the rest go on add-on codes. Facilities pick the initial code by CPT's hierarchy, with hydration ranked last; physician offices pick it by the main reason for the visit.
Each infusion visit is billed with the drug's HCPCS code in descriptor units plus its NDC, and with CPT administration codes chosen by hierarchy and infusion time. Qualigenix codes both from the infusion record and checks them against the authorization before submission.
Yes. We add JW with the documented discarded amount, or JZ when nothing was discarded, on each separately payable single-dose drug, as Medicare has required since July 1, 2023.
Yes. We take over existing accounts receivable and work aged infusion claims by payer and denial reason. Our A/R follow-up has reduced days in A/R from 54 to 36.